Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 12/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7877720 | 1.00 | LMNA (0.52) | LMNAMAPTCYP19A1CYP3A4NR3C1 | |
| SCHEMBL3396581 | 0.93 | LMNA (0.51) | LMNAMAPTCYP19A1CYP3A4NR3C1 | |
| SCHEMBL15994233 | 0.91 | LMNA (0.51) | LMNAMAPTCYP19A1CYP3A4NR3C1 | |
| SCHEMBL8587966 | 0.91 | LMNA (0.54) | LMNAMAPTCYP19A1CYP3A4NR3C1 | |
| SCHEMBL6521590 | 0.86 | LMNA (0.44) | LMNAMAPTCYP19A1CYP3A4NR3C1 | |
| SCHEMBL1847854 | 0.86 | LMNA (0.44) | LMNAMAPTCYP19A1CYP3A4NR3C1 | |
| SCHEMBL8661015 | 0.86 | LMNA (0.44) | LMNAMAPTCYP19A1CYP3A4NR3C1 | |
| SCHEMBL7204662 | 0.84 | LMNA (0.51) | LMNAMAPTCYP19A1CYP3A4NR3C1 | |
| SCHEMBL18662883 | 0.84 | LMNA (0.52) | LMNAMAPTCYP19A1CYP3A4NR3C1 | |
| SCHEMBL4807382 | 0.84 | LMNA (0.59) | LMNAMAPTCYP19A1CYP3A4NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006011148-A2 | NOVEL CRYSTALLINE FORMS OF 6ALPHA, 9ALPHA-DIFLUORO-11BETA HYDROXY-16ALPHA-METHYL-3-OXO-17ALPHA-PROPIONYLOXY-ANDROSTA-1,4-DIENE-17BETA-CARBOXYLIC ACID AND PROCESSES FOR PREPARATION THEREOF | CHEMAGIS LTD. (IL) | 2006-02-02 | — | — | WO | disclosed |
| EP-1611149-A1 | PROCESS FOR THE PREPARATION OF STEROIDAL CARBOTHIOIC ACID DERIVATIVES AND INTERMEDIATES | Alpharma APS (DK) | 2006-01-04 | — | — | EP | disclosed |
| EP-1534733-A2 | CONVENIENT SYNTHESIS OF S-FLUOROMETHYL 6ALPHA, 9ALPHA-DIFLUORO-11BETA-HYDROXY-16ALPHA- METHYL-17ALPHA-PROPIONYLOXY-3-OXOANDROSTA-1, 4-DIENE-17BETA-CARBOTHIOATE | Sun Pharmaceuticals Industries Ltd. (IN) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004087731-A1 | PROCESS FOR THE PREPARATION OF STEROIDAL CARBOTHIOIC ACID DERIVATIVES AND INTERMEDIATES | ALPHARMA APS (DK) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004001369-A2 | CONVENIENT SYNTHESIS OF S-FLUOROMETHYL 6ALPHA, 9ALPHA-DIFLUORO-11BETA-HYDROXY-16ALPHA- METHYL-17ALPHA-PROPIONYLOXY-3-OXOANDROSTA-1, 4-DIENE-17BETA-CARBOTHIOATE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2003-12-31 | — | — | WO | disclosed |
| EP-1133285-A1 | A PROCESS FOR PRODUCING PARTICLES WITH A CONVERTED AMORPHOUS AND/OR META-STABLE CRYSTALLINE REGION INTO CRYSTALLINE STATE | AstraZeneca AB (SE) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000030614-A1 | A PROCESS FOR PRODUCING PARTICLES WITH A CONVERTED AMORPHOUS AND/OR META-STABLE CRYSTALLINE REGION INTO CRYSTALLINE STATE | ASTRAZENECA AB (SE) | 2000-06-02 | — | — | WO | disclosed |